Trials / Completed
CompletedNCT02492321
A Multi-Center Environmental Study for the Treatment of Moderate to Severe Ocular Allergic Conjunctivitis
A Multi-Center, Randomized, Double-Masked, Vehicle-Controlled Evaluation of the Efficacy, Safety, and Tolerability of EBI-005 in Subjects With Moderate to Severe Ocular Allergic Conjunctivitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 250 (actual)
- Sponsor
- Eleven Biotherapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase III multi-center, double-masked, vehicle-controlled, randomized, parallel group study evaluating the efficacy, safety and tolerability of EBI-005 as compared to vehicle given as a topical ophthalmic solution in each eye to subjects with moderate to severe allergic conjunctivitis (AC) three times daily for 4 weeks. Approximately 250 subjects at approximately 8 centers in the US will be screened and enrolled into the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EBI-005 | |
| DRUG | Placebo Comparator |
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2015-11-01
- Completion
- 2015-12-01
- First posted
- 2015-07-08
- Last updated
- 2016-02-11
Locations
11 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02492321. Inclusion in this directory is not an endorsement.